📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 16:55
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
29 announcements match the current filters (relevance ≥ 5).
GSP Crop Science Q1 Revenue at ₹386 Cr; Targets 12-13% FY EBITDA Margin
GSP Crop Science reported Q1 FY27 revenue of ₹386 crore, up modestly from ₹377 crore in Q1 FY26, driven by stable domestic demand offsetting temporary export supply constraints. Q1 EBITDA margin stood at ~11%, with management guiding full-year EBITDA margins between 12% and 13%. Other income of ₹8.3 crore included a one-off gain of ₹5.7 crore from the sale of ~66,000 sq. meters of leased land to a promoter group entity. Management highlighted normal Kharif demand progression in Q2, which historically accounts for a large proportion of annual profits.
Confidence: HIGH
What changedPublication of the detailed Q1 FY27 earnings conference call transcript outlining operational performance, full-year margin targets, and one-off asset sale details.
Why it mattersProvides clarity that Q1 profit was partly aided by a non-recurring ₹5.7 crore land sale gain and sets baseline expectations for 12-13% EBITDA margins for FY27.
Q1 FY27 Revenue: ₹386 crQ1 FY26 Revenue: ₹377 crOne-off Land Sale Gain: ₹5.7 crExpected Full-Year EBITDA Margin: 12% to 13%Granted Patents: >100
📅 Short termPerformance in the immediate weeks hinges on peak Kharif application and supply fulfillment, with raw material constraints now resolved.
📈 Long termGrowth depends on increasing the share of proprietary patented combination products and expanding technical manufacturing to reduce import reliance.
⚠ Risk flags
- High seasonality with Q2 historically generating ~60% of annual PAT
- One-off gain of ₹5.7 cr from land sale to promoter entity flattered Q1 earnings
- Uneven monsoon distribution in key southern markets like AP, Telangana, and Karnataka
Key Highlights
Q1 FY27 revenue stood at ₹386 crore versus ₹377 crore in Q1 FY26
Reported Q1 EBITDA margin of ~11%, with full-year target guided at 12% to 13%
Other income of ₹8.3 crore included a one-off pre-tax gain of ₹5.7 crore from land sale
Q1 revenue mix comprised 45% domestic B2C, 45% domestic B2B, and 10% exports
Innovation pipeline includes 100+ granted patents and 100+ patent applications under process
👀 What to Watch
Track Q2 FY27 performance and monsoon progression in key southern states, as Q2 typically contributes the bulk of full-year profitability.
GSP Crop Science FY26 Revenue Grows 18% to ₹1,517 Cr; PAT Up 16% to ₹94.7 Cr
GSP Crop Science reported a strong FY26 with revenue from operations reaching ₹1,517.1 crore, a 17.8% increase over the previous year. EBITDA margins improved to 12.2% from 11.7% YoY, while Profit After Tax (PAT) grew 16.3% to ₹94.7 crore. The company is aggressively utilizing ₹170 crore from its ₹400 crore IPO proceeds for debt repayment, aiming for a total reduction of ₹220 crore to strengthen the balance sheet. Strategic focus is shifting toward high-margin patented products, which now contribute 20.73% to revenue compared to just 5.07% in FY22.
Confidence: HIGH
What changedThe company has transitioned to a listed entity with a clear roadmap for debt reduction and a higher focus on patented product revenue.
Why it mattersThe shift toward patented products and backward integration at the Saykha facility is designed to improve structural margins and reduce import dependency.
FY26 Revenue: ₹15,171 millionFY26 PAT: ₹947 millionEBITDA Margin (FY26): 12.2%IPO Primary Issuance: ₹240 CrDebt Repayment from IPO: ₹170 CrTotal Patents Granted: 112
📅 Short termThe market is likely to react positively to the double-digit revenue and profit growth alongside margin improvement.
📈 Long termLong-term value depends on the successful scaling of the international business (currently in 37 countries) and increasing the share of high-margin patented molecules.
⚠ Risk flags
- High raw material costs (₹9,589 million in FY26)
- Exposure to foreign exchange movements in international subsidiaries
- Regulatory risks associated with agrochemical registrations
Key Highlights
Revenue from operations increased to ₹15,171 million in FY26 from ₹12,874 million in FY25
PAT grew 16.3% YoY to ₹947 million with an EPS of ₹24.93
Patented products revenue share rose significantly to 20.73% in H1 FY25 from 5.07% in FY22
Company holds a robust IP portfolio with 112 granted patents and 114 applications pending
Planned debt reduction of ₹2,200 million using IPO proceeds to improve net debt-to-equity
👀 What to Watch
Investors should monitor the margin expansion resulting from the new Saykha intermediate plant's backward integration and the execution of the debt reduction plan.
17% PAT Growth to ₹264 Mn in Q1FY27; Gross Margins Expand to 36.9%
GSP Crop Science reported a 17% YoY increase in PAT to ₹264 Mn for Q1FY27, despite revenue remaining relatively flat at ₹3,860 Mn (up 2%). Gross margins improved significantly by 240 bps to 36.9% due to a favorable product mix, although EBITDA margins were slightly pressured at 11.0% by higher employee and operational costs. The company achieved a milestone by acquiring the remaining 21% stake in GSP Intermediates, making it a 100% subsidiary. Growth was primarily driven by the domestic B2C and B2B segments, while international business remained muted due to raw material constraints.
Confidence: HIGH
What changedGSP Crop Science reported its Q1FY27 financial results, finalized the full acquisition of its intermediate subsidiary, and commissioned new environmental infrastructure.
Why it mattersThe expansion in gross margins despite flat revenue indicates improved pricing power or a shift toward higher-margin products; full ownership of the intermediate unit enhances backward integration.
Revenue (Q1FY27): ₹3,860 MnPAT (Q1FY27): ₹264 MnGross Margin: 36.9%YoY PAT Growth: 17%Subsidiary Stake Acquired: 21%
📅 Short termThe stock may react positively to the margin expansion and double-digit PAT growth despite a volatile global operating environment.
📈 Long termFull ownership of GSP Intermediates and infrastructure upgrades at Saykha GIDC provide a structural base for better margin control and capacity utilization over the coming years.
⚠ Risk flags
- Volatility in raw material prices
- Geopolitical supply chain disruptions
- Muted international business performance
Key Highlights
PAT increased 17% YoY to ₹264 Mn for the quarter ended June 30, 2026.
Gross Profit grew 10% YoY to ₹1,424 Mn with margins expanding from 34.5% to 36.9%.
Completed 100% acquisition of GSP Intermediates Private Limited (GIPL) on June 11, 2026.
Revenue from operations stood at ₹3,860 Mn, reflecting a modest 2% YoY growth.
Commissioned new ETP & MEEA plant at Saykha GIDC to strengthen manufacturing infrastructure.
👀 What to Watch
Monitor the integration benefits of the now 100% owned GSP Intermediates and watch for a recovery in international sales as raw material supply constraints ease.
Sept 18 AGM Set; GSP Crop Science Reports Zero IPO Deviation and Appoints New Director
GSP Crop Science Limited approved its Q1 FY27 financial results on August 11, 2026, and confirmed that IPO proceeds have been utilized with zero deviation from the prospectus. The company scheduled its 41st Annual General Meeting (AGM) for September 18, 2026, with a dividend record date of September 11, 2026. Significant board changes include the appointment of Mr. Narayanan Pulukhool Nair as an Independent Director for a 5-year term, replacing Mr. Nakul Jayesh Sharedalal. Additionally, the board proposed an amendment to the Memorandum of Association (MOA) Object Clause to facilitate further business activities.
Confidence: HIGH
What changedThe company has refreshed its board composition with a new Independent Director and initiated a legal process to amend its business objects in the MOA.
Why it mattersThe MOA amendment is a critical legal step that typically precedes expansion into new product lines or services, while the confirmation of IPO fund usage ensures transparency.
AGM Date: September 18, 2026Dividend Record Date: September 11, 2026Director Appointment Term: 5 yearsIPO Proceed Deviation: NilSecretarial Auditor Term: 5 years
📅 Short termThe stock may see activity around the September 11 record date for dividends and in response to the Q1 earnings performance.
📈 Long termThe 5-year board and auditor appointments suggest a focus on governance stability, while the MOA change hints at future strategic diversification.
Key Highlights
41st Annual General Meeting scheduled for September 18, 2026, via video conferencing.
Record date for determining dividend eligibility fixed as September 11, 2026.
Appointment of Mr. Narayanan Pulukhool Nair as Independent Director for a 5-year term starting August 11, 2026.
Secretarial Auditor appointed for a 5-year block from FY 2026-27 to FY 2030-31.
Confirmed 0% deviation in the utilization of IPO proceeds for the quarter ended June 30, 2026.
👀 What to Watch
Investors should review the full Q1 financial results and the specific text of the proposed MOA amendment in the upcoming AGM notice to understand potential new business directions.
28% PAT Growth for GSP Crop Science in Q1; IPO Proceeds Fully Utilized at ₹113 Cr
GSP Crop Science reported a strong Q1 FY27 with a 28.4% YoY increase in Net Profit to ₹31.28 crore, despite a modest 6% growth in revenue to ₹424.2 crore. The company confirmed that the ₹113.05 crore raised through its March 2026 IPO has been 100% utilized as of June 30, 2026. Significant board changes were announced, including the appointment of a new Independent Director and a 5-year term for a new secretarial auditor. The company also set September 11, 2026, as the record date for its upcoming dividend.
Confidence: HIGH
What changedGSP Crop Science reported its first-quarter results for FY27, confirmed full utilization of IPO funds, and refreshed its board with a new Independent Director following a resignation.
Why it mattersThe strong profit growth indicates improved operational efficiency post-listing. Full utilization of IPO proceeds suggests the company has completed its planned capital deployment, which should ideally lead to capacity or efficiency gains in coming quarters.
Revenue (Q1 FY27): ₹4,242.05 millionNet Profit (Q1 FY27): ₹312.82 millionIPO Proceeds Utilized: ₹1,130.53 millionQ1 Revenue vs TTM Revenue: 26.4%Dividend Record Date: September 11, 2026
📅 Short termThe stock may see positive sentiment due to double-digit profit growth and the confirmation of disciplined IPO fund utilization.
📈 Long termThe long-term trajectory depends on how the company leverages the assets/projects funded by the IPO and the impact of the proposed MOA object clause changes.
⚠ Risk flags
- Resignation of an Independent Director due to other professional assignments
- Agrochemical sector sensitivity to monsoon and raw material price volatility
Key Highlights
Net Profit (PAT) grew 28.4% YoY to ₹312.82 million in Q1 FY27 from ₹243.54 million.
Revenue from operations increased 6% YoY to ₹4,242.05 million for the quarter ended June 30, 2026.
IPO proceeds of ₹1,130.53 million have been fully utilized as per the objects stated in the prospectus.
Basic EPS improved to ₹6.72 for the quarter, up from ₹5.24 in the same period last year.
Board approved the appointment of Chirag Shah & Associates as Secretarial Auditor for a 5-year term until FY 2030-31.
👀 What to Watch
Investors should monitor the upcoming AGM on September 18, 2026, for clarity on the proposed alteration of the Memorandum of Association (MOA) and the company's growth strategy now that IPO funds are fully deployed.
GSP Crop Science Q1 PAT Rises 28% to ₹31.28 Cr; Appoints New Independent Director
GSP Crop Science reported a strong Q1 FY27 with standalone revenue growing 6% YoY to ₹424.2 crore and PAT increasing 28.4% YoY to ₹31.28 crore. The company confirmed that its IPO proceeds of ₹113.05 crore have been fully utilized as of June 30, 2026, with no deviations. Management changes include the resignation of Independent Director Nakul Sharedalal and the appointment of Narayanan Pulukhool Nair for a 5-year term. The board has also scheduled the 41st AGM for September 18, 2026, with a dividend record date of September 11, 2026.
Confidence: HIGH
What changedThe company has fully deployed its IPO capital and refreshed its board composition while delivering double-digit profit growth in the first quarter of the new fiscal year.
Why it mattersStrong earnings growth post-listing and transparent utilization of IPO funds build investor confidence in management's execution capabilities within the competitive agrochemical sector.
Revenue (Q1 FY27): ₹4,242.05 millionPAT (Q1 FY27): ₹312.82 millionPAT Growth (YoY): 28.4%IPO Proceeds Utilized: ₹1,130.53 millionDividend Record Date: September 11, 2026
📅 Short termThe stock may see positive momentum in the coming days due to the healthy 28% profit growth and the announcement of the dividend record date.
📈 Long termSustained growth in the agrochemical space and the successful deployment of IPO funds for stated objectives suggest a stable long-term trajectory, though board stability remains important.
⚠ Risk flags
- Resignation of Independent Director citing preoccupation
- Proposed alteration of MOA Object Clause (details pending shareholder approval)
Key Highlights
Standalone Revenue from Operations increased to ₹4,242.05 million in Q1 FY27 from ₹4,002.42 million YoY.
Net Profit for the quarter rose 28.4% to ₹312.82 million compared to ₹243.54 million in the same quarter last year.
Full utilization of IPO proceeds amounting to ₹1,130.53 million confirmed by the board.
Appointment of Mr. Narayanan Pulukhool Nair as Independent Director for a 5-year term effective August 11, 2026.
Record date for dividend entitlement set for September 11, 2026.
👀 What to Watch
Investors should monitor the upcoming AGM on September 18 for details on the proposed alteration to the Memorandum of Association (Object Clause) and the final dividend payout details.
GSP Crop Science Q1 PAT Rises 28% to ₹31.28 Cr; Dividend Record Date Set for Sept 11
GSP Crop Science reported a 6% YoY increase in revenue to ₹424.2 crore for Q1 FY27. Net profit grew significantly by 28.4% YoY to ₹31.28 crore, indicating improved operational efficiency. The company confirmed that the ₹113.05 crore raised through its IPO has been fully utilized as of June 30, 2026. Additionally, the board has set September 11, 2026, as the record date for dividends and announced a change in the Independent Director position.
Confidence: HIGH
What changedThe company reported its first-quarter financial results post-IPO, confirmed full utilization of IPO funds, and refreshed its board composition with a new Independent Director.
Why it mattersStrong bottom-line growth (28%+) despite modest revenue growth (6%) suggests margin expansion. Full utilization of IPO proceeds indicates the company has completed its planned capital deployment phase.
Q1 Revenue: ₹4,242.05 millionQ1 PAT: ₹312.82 millionPAT Growth (YoY): 28.4%IPO Proceeds Utilized: ₹1,130.53 millionDividend Record Date: September 11, 2026
📅 Short termThe stock is likely to react positively to the 28% profit growth and the upcoming dividend record date.
📈 Long termThe company is transitioning into a listed entity with fully deployed IPO capital; long-term value will depend on the execution of its expanded business objects and agrochemical market cycles.
⚠ Risk flags
- Resignation of an Independent Director who chaired the Stakeholder Relationship Committee
- Cyclicality inherent in the pesticides and agrochemicals industry
Key Highlights
Revenue from operations increased 6% YoY to ₹4,242.05 million in Q1 FY27.
Net profit (PAT) grew 28.4% YoY to ₹312.82 million compared to ₹243.54 million in the previous year.
IPO proceeds of ₹1,130.53 million have been 100% utilized as of the quarter ended June 30, 2026.
Dividend record date is fixed for September 11, 2026, with the AGM scheduled for September 18, 2026.
Appointment of Mr. Narayanan Pulukhool Nair as Independent Director for a 5-year term following the resignation of Mr. Nakul Sharedalal.
👀 What to Watch
Investors should monitor the upcoming AGM on September 18 for clarity on the proposed alteration of the Memorandum of Association (MOA) object clause, which may signal new business directions.
₹31.28 Cr Q1 Profit: GSPCROP Reports 28% YoY Growth; Sets Sept 11 Dividend Record Date
GSP Crop Science reported a 28.4% YoY increase in standalone net profit to ₹312.82 million for Q1 FY27, despite a modest 6% revenue growth to ₹4,242.05 million. The company has fixed September 11, 2026, as the record date for its dividend, with the Annual General Meeting scheduled for September 18. Notably, the company confirmed that the ₹1,130.53 million raised through its IPO has now been fully utilized. Management also announced the appointment of a new Independent Director following the resignation of Mr. Nakul Jayesh Sharedalal.
Confidence: HIGH
What changedThe company has transitioned from its IPO phase to full capital utilization while delivering strong double-digit profit growth in Q1 FY27.
Why it mattersThe 28% profit growth on 6% revenue growth suggests significant margin expansion or operational efficiency. Full utilization of IPO funds indicates the company has deployed capital into its intended growth projects.
Net Profit (Q1 FY27): ₹312.82 millionRevenue from Operations: ₹4,242.05 millionIPO Proceeds Utilized: ₹1,130.53 millionDividend Record Date: 11-Sep-2026EPS (Basic): ₹6.72
📅 Short termPositive sentiment is expected due to the earnings beat and dividend announcement; the stock may see increased activity leading up to the September 11 record date.
📈 Long termThe company's ability to maintain high profit growth post-IPO utilization will be critical for long-term valuation re-rating in the agrochemical sector.
⚠ Risk flags
- Resignation of Independent Director Nakul Jayesh Sharedalal
- Proposed alteration of MOA object clause indicates potential shift or expansion in business scope
Key Highlights
Standalone Net Profit increased 28.4% YoY to ₹312.82 million in Q1 FY27
Revenue from operations grew 6% YoY to ₹4,242.05 million from ₹4,002.42 million
Record date for dividend entitlement is confirmed as September 11, 2026
IPO proceeds totaling ₹1,130.53 million have been 100% utilized as of June 30, 2026
Basic EPS for the quarter rose to ₹6.72 from ₹6.24 in the previous year's corresponding period
👀 What to Watch
Investors should monitor the upcoming AGM on September 18 for the final dividend declaration and updates on the proposed alteration of the Memorandum of Association (MOA) object clause, which may signal new business directions.
GSP Crop Science Q1 PAT Rises 28% to ₹31.28 Cr; IPO Proceeds Fully Utilized
GSP Crop Science reported a steady Q1 FY27 with standalone revenue growing 6% YoY to ₹424.2 crore. Net profit (PAT) saw a more significant jump of 28.4% YoY, reaching ₹31.28 crore, driven by improved operational efficiencies. The company confirmed that the ₹113.05 crore raised through its IPO has been 100% utilized with zero deviation from the objects stated in the prospectus. Additionally, the board has set September 11, 2026, as the record date for the upcoming dividend and announced management changes including a new Independent Director.
Confidence: HIGH
What changedThe company has transitioned from reporting IPO fund utilization to full deployment and reported a strong double-digit growth in bottom-line profits for the first quarter of FY27.
Why it mattersThe 28% PAT growth suggests improving margins in a competitive agrochemical market, and the clean report on IPO proceeds utilization builds management credibility for the recently listed entity.
Revenue (Q1 FY27): ₹4,242.05 millionPAT (Q1 FY27): ₹312.82 millionPAT Growth (YoY): 28.4%IPO Proceeds Utilized: ₹1,130.53 millionRecord Date for Dividend: September 11, 2026
📅 Short termThe stock may see positive sentiment due to the strong profit growth and the confirmation of no deviations in IPO fund usage.
📈 Long termThe company's ability to maintain 20%+ profit growth in the agrochemical sector will be key to its long-term valuation re-rating.
⚠ Risk flags
- Resignation of an Independent Director (Chairman of Stakeholder Relationship Committee)
- Seasonal volatility inherent in the pesticides and agrochemicals industry
Key Highlights
Standalone Revenue from Operations increased to ₹4,242.05 million in Q1 FY27 from ₹4,002.42 million in Q1 FY26.
Net Profit for the quarter rose 28.4% YoY to ₹312.82 million compared to ₹243.54 million in the previous year.
IPO proceeds of ₹1,130.53 million are now fully utilized as of June 30, 2026, with no deviations reported.
Record date for dividend entitlement is fixed for September 11, 2026, with the AGM scheduled for September 18, 2026.
Appointment of Mr. Narayanan Pulukhool Nair as an Independent Director for a 5-year term following the resignation of Mr. Nakul Jayesh Sharedalal.
👀 What to Watch
Investors should monitor the upcoming AGM for clarity on the proposed 'Alteration of Object Clause' in the Memorandum of Association and the final dividend payout details.
GSP Crop Science Sets Sept 11 Record Date for Dividend; Appoints New Independent Director
GSP Crop Science Limited approved its unaudited financial results for the quarter ended June 30, 2026, and confirmed zero deviation in the utilization of IPO proceeds. The company has scheduled its 41st Annual General Meeting for September 18, 2026, and fixed September 11, 2026, as the record date for dividend payments. Significant board changes occurred with the appointment of Mr. Narayanan Pulukhool Nair (28 years of experience) as an Independent Director and the resignation of Mr. Nakul Jayesh Sharedalal. The board also proposed an alteration to the company's Object Clause in the Memorandum of Association, pending shareholder approval.
Confidence: HIGH
What changedThe company has finalized its Q1 reporting cycle, established dividend and AGM timelines, and restructured its board with a new Independent Director appointment and one resignation.
Why it mattersThe appointment of a director with 28 years of experience in supply chain and marketing (formerly with ADAMA and Ranbaxy) strengthens the board, while the MOA object clause change suggests a potential shift or expansion in business scope.
Record Date: September 11, 2026AGM Date: September 18, 2026Director Appointment Term: 5 yearsIPO Proceeds Deviation: NilDirector Experience: 28 years
📅 Short termThe stock may see routine activity around the dividend record date and the release of the detailed Q1 financial performance figures.
📈 Long termThe long-term impact depends on the nature of the MOA object clause alteration and the strategic contribution of the new board member to the company's supply chain and marketing efforts.
⚠ Risk flags
- Resignation of an Independent Director
- Proposed alteration of MOA Object Clause (uncertainty regarding new business directions)
Key Highlights
Record date for dividend eligibility fixed for September 11, 2026
41st Annual General Meeting scheduled for September 18, 2026, at 11:30 a.m.
Appointment of Mr. Narayanan Pulukhool Nair as Independent Director for a 5-year term starting August 11, 2026
Confirmed zero deviation or variation in the utilization of IPO proceeds for the quarter ended June 30, 2026
Resignation of Independent Director Mr. Nakul Jayesh Sharedalal effective August 11, 2026, due to professional preoccupations
👀 What to Watch
Investors should review the full Q1 financial results once published to assess operational performance and monitor the AGM notice for details on the proposed changes to the company's Object Clause.
GSP Crop Science to Consolidate ₹152.77 Cr Revenue via Merger of Two Subsidiaries
GSP Crop Science has approved a Scheme of Arrangement to merge its wholly-owned subsidiary Rajdhani Petrochemicals (RPPL) and demerge the manufacturing unit of GSP Intermediates (GIPL) into itself. RPPL contributes ₹124.51 crore in revenue (approx. 7.6% of parent revenue), while the GIPL unit adds ₹28.26 crore. As both entities are 100% subsidiaries, no new shares will be issued, ensuring zero equity dilution for shareholders. The consolidation, effective from April 1, 2026, aims to optimize borrowing costs and streamline corporate compliance.
Confidence: HIGH
What changedThe company is consolidating its corporate structure by absorbing a wholly-owned subsidiary and a specific manufacturing division into the main listed entity.
Why it mattersThis move simplifies the corporate structure, reduces the multiplicity of legal compliances, and allows for better utilization of combined resources and a stronger consolidated balance sheet.
RPPL Total Income (FY26): ₹124.51 crGIPL Demerged Unit Turnover (FY26): ₹28.26 crParent Total Income (FY26): ₹1,627.61 crCombined Revenue vs Parent: ~9.38%Appointed Date: April 1, 2026
📅 Short termThe market is likely to view the consolidation positively due to the lack of equity dilution and the potential for administrative cost savings.
📈 Long termStructural simplification and resource pooling should lead to improved operational efficiency and optimized borrowing costs over the next 2-3 years.
⚠ Risk flags
- Regulatory approval delays from NCLT
- Integration of manpower and operational processes
Key Highlights
Amalgamation of RPPL which reported a total income of ₹124.51 crore for FY26
Demerger of GIPL's manufacturing unit with a turnover of ₹28.26 crore into the parent
Zero equity dilution as no new shares will be issued to the parent company
Combined revenue contribution from both units represents ~9.38% of the parent's FY26 income
Parent company net worth stood at ₹734.47 crore as of March 31, 2026
👀 What to Watch
Monitor the timeline for NCLT and regulatory approvals to confirm when operational synergies and cost savings will begin reflecting in the consolidated margins.
GSP Crop Science to merge WOS Rajdhani Petrochemicals; ₹124.5 Cr income to be consolidated
GSP Crop Science's board has approved a Scheme of Arrangement to merge its wholly-owned subsidiary Rajdhani Petrochemicals (RPPL) and demerge the manufacturing unit of GSP Intermediates (GIPL) into the parent company. RPPL brings an annual income of ₹124.51 crore (approx. 7.6% of GSP's FY26 income) and a net worth of ₹64.54 crore. As both are 100% subsidiaries, no new shares will be issued, ensuring zero dilution for existing shareholders. The restructuring, effective from the appointed date of April 1, 2026, aims to streamline operations and optimize borrowing costs within the agrochemical segment.
Confidence: HIGH
What changedGSP Crop Science is consolidating its corporate structure by absorbing one subsidiary and a specific manufacturing unit from another subsidiary.
Why it mattersThis simplifies the legal structure, reduces administrative and compliance costs, and brings the assets and liabilities of subsidiaries directly onto the parent's balance sheet for better capital utilization.
RPPL Total Income (FY26): ₹12450.90 LakhGIPL Unit Turnover: ₹2825.94 LakhGSP Net Worth (FY26): ₹73446.6 LakhRPPL Income vs GSP Income: ~7.65%Appointed Date: April 1, 2026
📅 Short termNeutral; this is a procedural announcement for internal restructuring with no immediate impact on share price or capital structure.
📈 Long termModest positive due to administrative synergies, simplified regulatory compliance, and consolidated pool of finances.
⚠ Risk flags
- Regulatory and NCLT approval delays
Key Highlights
Merger of RPPL adds ₹124.51 crore in total income to the parent entity based on FY26 figures
Demerger of GIPL's manufacturing unit contributes an additional ₹28.26 crore in turnover
No new equity shares will be issued; existing shares in subsidiaries will be cancelled upon the scheme becoming effective
The parent company, GSP Crop Science, reported a net worth of ₹734.47 crore as of March 31, 2026
The appointed date for the entire scheme is set for April 1, 2026
👀 What to Watch
Watch for the NCLT approval timeline and the subsequent integration of these units into the standalone financial reporting to assess operational synergy benefits.
GSP Crop Science Completes Acquisition of 21% Stake in GSP Intermediates; Now 100% Subsidiary
GSP Crop Science Limited has finalized the acquisition of the remaining 21% equity stake in its subsidiary, GSP Intermediates Private Limited (GIPL). The company acquired 31,50,000 equity shares of face value Rs. 10 each, completing the transaction on June 11, 2026. Consequently, GIPL has become a wholly-owned subsidiary of GSP Crop Science. This consolidation allows the company to have full control over GIPL's operations and financial performance.
Key Highlights
Acquired 31,50,000 equity shares representing the balance 21% stake in GSP Intermediates Private Limited.
GSP Intermediates Private Limited (GIPL) is now a 100% wholly-owned subsidiary of the company.
The acquisition was completed on June 11, 2026, following an initial board approval/intimation on May 14, 2026.
Consolidation of ownership is expected to streamline supply chain operations and financial reporting.
👀 What to Watch
Investors should view this consolidation as a positive move for long-term operational efficiency and full accrual of subsidiary profits. Monitor the next quarterly results for the impact of full consolidation on the bottom line.
GSP Crop Science Completes Acquisition of Balance 21% Stake in GSP Intermediates
GSP Crop Science Limited has finalized the acquisition of the remaining 21% equity stake in its subsidiary, GSP Intermediates Private Limited (GIPL), on June 11, 2026. The company acquired 31,50,000 equity shares at a face value of Rs. 10 each from existing shareholders. Following this transaction, GIPL's status has transitioned from a subsidiary to a 100% wholly-owned subsidiary of GSP Crop Science. This consolidation allows the parent company full control over its intermediate manufacturing operations.
Key Highlights
Acquired balance 21% equity stake consisting of 31,50,000 equity shares.
GSP Intermediates Private Limited (GIPL) is now a 100% wholly-owned subsidiary.
The acquisition was completed on June 11, 2026, at approximately 11:30 PM.
The move follows an initial board intimation regarding the acquisition dated May 14, 2026.
👀 What to Watch
Investors should view this as a positive step toward corporate structure simplification and operational synergy. Monitor the next quarterly results for any impact on consolidated margins due to full ownership.
GSP Crop Science Reports Zero Deviation in Utilization of ₹2,400 Million IPO Proceeds
GSP Crop Science Limited has officially confirmed that there is no deviation or variation in the utilization of funds raised through its recent Initial Public Offering (IPO). The company raised ₹2,400 million via a fresh issue on March 20, 2026, and has already deployed ₹965 million toward debt repayment. The Audit Committee and monitoring agency, CRISIL Ratings, have reviewed and verified that the fund usage aligns perfectly with the objects stated in the prospectus. This transparency is a positive signal for new investors regarding management's execution of the stated financial strategy.
Key Highlights
Raised ₹2,400 million through a fresh issue and ₹1,600 million via Offer for Sale (OFS) in March 2026.
Utilized ₹965 million out of the allocated ₹1,700 million for the repayment of outstanding borrowings.
Spent ₹107.64 million on general corporate purposes and ₹75.05 million on IPO-related expenses.
Confirmed zero deviation from the prospectus objects for the financial year ended March 31, 2026.
Monitoring agency CRISIL Ratings Limited and the Audit Committee have validated the utilization report.
👀 What to Watch
Investors should take confidence in the company's adherence to its IPO commitments and disciplined fund deployment. Continue to monitor the utilization of the remaining ₹1,252.31 million in subsequent quarters to ensure continued alignment with growth objectives.
GSP Crop Science Pledges Additional 13.03% Stake in Subsidiary GIPL to Aditya Birla Capital
GSP Crop Science Limited has created a further pledge on 15,43,500 equity shares of its subsidiary, GSP Intermediates Private Limited (GIPL). This pledge, in favor of Aditya Birla Capital Limited, serves as security for a term loan availed by the subsidiary. With this addition, a total of 73,50,000 shares (approximately 62% of GIPL's total capital) are now encumbered. The company maintains its 79% ownership stake in GIPL, and the transaction does not result in any change of control.
Key Highlights
Pledged 15,43,500 equity shares (13.03% of GIPL) to Aditya Birla Capital on May 26, 2026.
Total shares of GIPL under pledge now stand at 73,50,000, up from 58,06,500 previously.
The pledge acts as security for a term loan taken by the subsidiary company GIPL.
GSP Crop Science continues to hold a 79% majority stake (1,18,50,000 shares) in GIPL.
No change in management control or ownership structure of the subsidiary company.
👀 What to Watch
Investors should monitor the financial health and debt-servicing capability of the subsidiary GIPL, as a significant portion of its shares are now pledged. While ownership remains intact, high encumbrance levels are a key risk factor to track in future quarterly reports.
GSP Crop Science FY26 Net Profit rises 19% to ₹898M; ₹1 Dividend declared
GSP Crop Science reported a strong performance for the financial year ended March 31, 2026, with revenue from operations growing 14% YoY to ₹16,059.06 million. Net profit increased by 18.8% to ₹898.35 million compared to ₹755.90 million in the previous year. The company also announced a final dividend of ₹1.00 per share and a transition in the CFO role, with Pranav Chitre taking over from June 1, 2026.
Key Highlights
Annual Revenue from Operations increased 14% YoY to ₹16,059.06 million in FY26.
Net Profit for the full year rose to ₹898.35 million from ₹755.90 million in FY25.
Recommended a final dividend of ₹1.00 per equity share (10% of face value).
Appointed Mr. Pranav Chitre as Chief Financial Officer effective June 1, 2026.
Cash and Cash Equivalents significantly improved to ₹1,538.25 million from ₹88.94 million YoY.
👀 What to Watch
Investors should take note of the healthy double-digit growth in both revenue and profit; the stock remains a 'Watch' to see how the new CFO and the re-designated Strategy Director drive future growth.
GSP Crop Science FY26 Net Profit Rises 19% to ₹898M; Recommends ₹1 Dividend
GSP Crop Science reported a solid performance for the financial year ended March 31, 2026, with revenue from operations increasing 14% to ₹16,059.06 million. Net profit grew by 18.8% year-on-year to reach ₹898.35 million. The company recommended a final dividend of ₹1.00 per share and announced a transition in leadership with Pranav Chitre appointed as the new CFO. A significant increase in cash reserves to ₹1,538.25 million was noted, primarily driven by a ₹2,400 million fresh issue of shares during the year.
Key Highlights
Annual Revenue from Operations grew 14% YoY to ₹16,059.06 million from ₹14,086.94 million.
Net Profit for FY26 increased to ₹898.35 million compared to ₹755.90 million in the previous year.
Recommended a final dividend of ₹1.00 per equity share (10% of face value of ₹10).
Cash and cash equivalents surged to ₹1,538.25 million from ₹88.94 million, aided by a ₹2,400 million share issuance.
Appointed Pranav Chitre as Chief Financial Officer effective June 1, 2026, succeeding Shail Jayesh Shah.
👀 What to Watch
Investors should view the steady growth in profitability and the strengthened cash position as positive indicators of the company's scaling capabilities. Monitor the strategic shift as the former CFO moves into a dedicated Strategy and Corporate Affairs role.
GSP Crop Science FY26 Revenue Rises 14% to ₹16,059M; Declares ₹1 Dividend & Appoints New CFO
GSP Crop Science reported a steady performance for FY26, with revenue from operations growing 14% YoY to ₹16,059.06 million. Net profit for the year increased to ₹898.35 million from ₹755.90 million in the previous fiscal, representing an 18.8% growth. The board has recommended a final dividend of ₹1.00 per equity share (10% of face value). Additionally, the company announced a management transition with Mr. Pranav Chitre taking over as CFO from June 1, 2026, while the current CFO moves to a strategy-focused executive role.
Key Highlights
Revenue from operations grew 14% YoY to ₹16,059.06 million in FY26 compared to ₹14,086.94 million in FY25.
Net profit for the full year increased by 18.8% to ₹898.35 million from ₹755.90 million.
Recommended a final dividend of ₹1.00 per share on a face value of ₹10 for FY26.
Appointed Mr. Pranav Chitre as the new Chief Financial Officer effective June 1, 2026.
Basic and Diluted Earnings Per Share (EPS) improved to ₹22.88 from ₹19.37 in the previous year.
👀 What to Watch
Investors should take note of the consistent double-digit growth in both revenue and profitability. The planned management transition and dividend payout reflect corporate stability and a positive outlook for the upcoming fiscal year.
GSP Crop Science FY26 Net Profit Rises 19% to ₹898M; Recommends ₹1 Dividend
GSP Crop Science reported a robust performance for FY26, with total income growing 14% year-on-year to ₹16,276.08 million. Net profit for the year increased by 18.8% to ₹898.35 million, up from ₹755.90 million in the previous fiscal. The board has recommended a final dividend of ₹1.00 per equity share (10% of face value). Additionally, the company announced a leadership transition with Mr. Pranav Chitre taking over as CFO as the incumbent moves to a strategy-focused role.
Key Highlights
Annual revenue from operations increased 14% YoY to ₹16,059.06 million in FY26
Net profit for the full year grew to ₹898.35 million compared to ₹755.90 million in FY25
Recommended a final dividend of ₹1.00 per share (10% of face value of ₹10)
Cash and cash equivalents surged to ₹1,538.25 million from ₹88.94 million YoY
Mr. Pranav Chitre appointed as Chief Financial Officer effective June 1, 2026
👀 What to Watch
Investors should view the steady growth in profitability and the dividend payout as positive signs of financial health. Monitor the transition in finance leadership and the company's execution under the new strategic focus.
